Nuvectis Q2: $115M Raise Closes, Haisco Deal Activated, NXP100 Approved in China
NVCT has more than doubled off its 52-week low of $5.55.
Summary
Nuvectis closed a $115M offering, activated the Haisco license, and reported NXP100's Chinese approval — transforming its pipeline and balance sheet in a single quarter.
Key Events · Earnings and Guidance · NVCT
-
$115M Follow-On Offering Closed
Completed sale of 5.75M shares at $20.00 each, generating $106.3M in net proceeds. The offering, which included full exercise of the underwriters' option, strengthens the balance sheet and funds the Haisco upfront payment and pipeline development.
-
Haisco License Effective; $20M Upfront Paid
The exclusive license for NXP100 and NXP200 became effective July 1, 2026, upon closing of the offering. Nuvectis paid Haisco a $20.0 million upfront fee and gained ex-China rights to two clinical-stage assets.
-
NXP100 Approved in China for PNH
Ciprocopan (NXP100) received marketing approval from China's NMPA for treatment-naive paroxysmal nocturnal hemoglobinuria, marking the first regulatory approval for a Nuvectis pipeline candidate.
-
Q2 Net Loss Widens to $7.0M
Net loss increased to $7.0M from $6.3M a year ago, driven by a 30% rise in R&D expenses to $4.7M, primarily for NXP900 clinical trials and manufacturing. G&A declined 16% to $2.5M.
Analysis · NVCT · Life Sciences
Nuvectis Pharma's Q2 2026 10-Q confirms the closing of a $115 million follow-on offering, the effectiveness of the Haisco license for NXP100 and NXP200, and the first marketing approval for NXP100 in China. The offering, priced at $20.00 per share, brought in net proceeds of $106.3 million, extending the cash runway to at least 12 months. The Haisco deal became effective July 1, triggering a $20 million upfront payment. NXP100's Chinese approval for treatment-naive PNH validates the asset, though U.S. and EU approvals remain uncertain. The company reported a $7.0 million net loss for Q2, with R&D spend rising 30% year-over-year to $4.7 million, reflecting increased clinical activity. With $22.2 million in cash at quarter-end and the new capital, Nuvectis is funded to advance its pipeline, but will need additional financing to complete later-stage trials.
At the time of this filing, NVCT was trading at $18.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $681M. The 52-week trading range was $5.55 to $29.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.